Thomapyrin INTENSIV by Sanofi - dual-action pain relief in focus

Thomapyrin INTENSIV sits in many German bathroom cabinets, the slim blister pack wedged between plasters and nasal spray. One tablet with the distinctive white imprint dissolves quickly on the tongue with a slightly bitter edge, promising to take the edge off a pounding, light-sensitive headache.

Combination tailored for headache relief

Thomapyrin is a branded pain reliever line marketed by Sanofi in Germany, with Thomapyrin INTENSIV positioned for moderate headache and migraine relief. The formula combines 250 mg acetylsalicylic acid, 250 mg paracetamol and 50 mg caffeine per tablet. One tablet taken with water is the standard adult dose, with a maximum of six tablets per day advised.

The official German Sanofi consumer information stresses that the triple combination aims to shorten the time to pain relief and increase the intensity of pain reduction compared with single-substance analgesics. Acetylsalicylic acid and paracetamol act as analgesic and antipyretic agents, while caffeine is intended to enhance the analgesic effect.

Sanofi’s OTC strategy in Germany

In Germany, Thomapyrin belongs to Sanofi’s over-the-counter (OTC) portfolio and is sold exclusively through pharmacies, both brick-and-mortar and reputable online outlets. Sanofi highlights the brand as part of its consumer healthcare segment, which includes other self-medication products such as allergy and digestive remedies.

Paul Hudson, CEO of Sanofi, has repeatedly emphasized the importance of the Consumer Healthcare business as a stable cash generator alongside prescription medicines. In interviews and presentations, he points to established brands like Thomapyrin as examples of how Sanofi leverages local name recognition in European markets. The German Sanofi site positions Thomapyrin INTENSIV as a product for adults and adolescents aged 12 years and older, with clear dosing and contraindication guidance.

Clinical background and positioning

Behind the everyday use sits a fairly technical concept: combining two analgesics with caffeine in one tablet. Clinical data referenced by Sanofi and the German product information show that fixed combinations of acetylsalicylic acid and paracetamol, plus caffeine, can improve response rates in tension-type headache compared with either component alone. The product is explicitly not positioned for chronic pain management but for episodic moderate headache and migraine attacks.

A detailed summary of product characteristics is provided through German regulatory channels and pharmaceutical databases. There, Thomapyrin INTENSIV is categorized among non-opioid analgesics in ATC group N02BA, with clear warnings around gastrointestinal bleeding risk, liver function issues and interactions with other medicines that also contain paracetamol or acetylsalicylic acid.

Packaging, dosing and user experience

On the shelf, Thomapyrin INTENSIV is easy to spot. The box uses a deep blue background with a stylized head silhouette and radiating yellow-orange lines from the temple area, a visual shorthand for throbbing pain. The active ingredients are listed clearly on the front in milligram amounts, with the Sanofi logo in the corner.

Typical pack sizes include blisters of 10 or 20 tablets, aimed at occasional use rather than bulk chronic dosing. In pharmacy practice, pharmacists often place Thomapyrin INTENSIV near other combined analgesics, emphasizing to customers that it should not be taken together with additional paracetamol or aspirin products. When a pharmacist slides a blister across the cool counter surface, the clink of tablets inside is a reminder to read the leaflet first.

Pricing and availability

Thomapyrin INTENSIV is sold without a prescription in Germany, but only in pharmacies, which can set their own retail prices within a range. Observed online pharmacy prices for a 20-tablet pack typically fall around 6 to 8 euro, depending on provider and promotions. Because the product is not subject to fixed statutory pricing, competition between pharmacies influences the final consumer price.

The German Sanofi site confirms continuous availability, with Thomapyrin as a long-established brand. Meanwhile, price comparison services such as medication price comparison portals list dozens of pharmacy offers across the country. For B2B customers like pharmacy chains and wholesalers, Sanofi supplies Thomapyrin INTENSIV through regular distribution channels as part of its consumer healthcare assortment.

Regulatory and safety aspects

As with all combined analgesics in Germany, Thomapyrin INTENSIV is subject to strict regulatory oversight. The German Federal Institute for Drugs and Medical Devices (BfArM) maintains dossiers and safety information on such products. Sanofi, as the marketing authorization holder, must update product information when new safety data emerge, such as insights on gastrointestinal risks of acetylsalicylic acid or hepatotoxicity associated with paracetamol overdose.

The patient information leaflet, accessible via pharmaceutical document repositories, instructs users not to exceed recommended doses and to avoid combining the product with alcohol. It also explicitly warns pregnant women and patients with pre-existing gastrointestinal or liver disease to consult a physician or pharmacist before using Thomapyrin INTENSIV.

Role inside Sanofi and impact on the share

From Sanofi’s perspective, Thomapyrin INTENSIV is not a global blockbuster, but a solid legacy brand in a mature OTC segment. Consumer healthcare sales, including pain relief products in Germany, provide recurring revenue with relatively low development costs compared with novel biologicals or vaccines. This helps smooth the group’s earnings profile and supports investment capacity in higher-risk R&D projects.

For the Sanofi S.A. share, which is listed on Euronext Paris and traded in euro under ISIN FR0000120578, the cumulative performance of brands like Thomapyrin in Germany contributes to the stability of the Consumer Healthcare segment and thereby influences investor perception of cash flow resilience.